Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


Italian health ministry seeks damages of $1.6 billion for Novartis and Roche collusion

The damages follow a March guilty verdict that the companies inflated the price of Lucentis

Major Swiss pharmaceutical companies Novartis and Roche were fined a combined $250 million for drug collusion in March, but if Italy’s health ministry has its way, the actual price will be much, much higher.

On May 28, the health ministry announced that it will seek damages of €1.2 billion ($1.6 billion) from the two companies for working together to push the cost of the jointly-marketed drug Lucentis higher. In a statement, the health ministry said that this move is a result of Novartis and Roche had causing “considerable damage” to Italian citizens through their actions.

In the original March guilty verdict, the Italian Competition Authority found that the two companies pushed doctors to exclude other drugs in favor of Lucentis, which treats age-related macular degeneration by blocking the growth of blood vessels in the eye. According to the Authority, Novartis and Roche targeted the drug Avastin, an older, less expensive Roche drug used to treat the same ailments. By creating artificial differences between the products the companies sought to draw customers to Lucentis.

The health ministry claims that it is seeking damages for all incidents occurring between 2012 and 2014. However, its claims will be met with a fight. Novartis told the Wall Street Journal that it "strongly denies allegations about anticompetitive practices between Novartis and Roche in Italy," and a Roche spokesperson found the health ministry’s claims baseless.

As noted previously on InsideCounsel, Italy’s off-practice label regulations are at the heart of this case. Drug makers, such as Novartis and Roche, are only allowed to market drugs for specific uses that have been approved by regulatory agents. Doctors, however, are free to prescribe approved drugs for whatever they see fit. This disconnect caused Roche to say that the original Authority verdict, “openly encourages and promotes the widespread unlicensed intravitreal use of Avastin contrary to the requirements of European and Italian regulatory law,” and that it “undermines the European regulatory framework designed to protect patient safety.”


For more legal news in the healthcare industry, check out these recent articles:

Patent reform proposal withers in Senate

Medtronic settles heart valve patent war with Edwards LifeSciences

Court rules no patent for Dolly the cloned sheep

Medical device company Medtronic agrees to settle $22 million suit in bone graft drug case

Executive Editor

author image

Chris DiMarco

Chris DiMarco, Executive Editor of InsideCounsel magazine, has a background in multimedia production with previous involvement in projects in which he developed and created content...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.